Volume 27, Number 11—November 2021
Research
Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA
Table 2
Characteristics | No. (%) participants, n = 8,108 |
---|---|
Sex | |
F | 4,335 (53.5) |
M |
3,773 (46.5) |
Age, y | |
12–<18 | 755 (9.3) |
18–<45 | 3,366 (41.5) |
45–64 | 2,345 (28.9) |
65–74 | 1,087 (13.4) |
>75 |
555 (6.8) |
Ethnicity, n = 8044 | |
Hispanic | 528 (6.6) |
Non-Hispanic |
7,516 (93.4) |
Race, n = 7,839 | |
White | 7,452 (95.1) |
Black or African American | 34 (0.4) |
American Indian or Alaska Native | 32 (0.4) |
Asian | 159 (2.0) |
Native Hawaiian or other Pacific Islander | 40 (0.5) |
Multiracial |
122 (1.6) |
Underlying conditions | |
Diabetes | 508 (6.3) |
Hypertension | 1,078 (13.3) |
Cardiovascular disease | 354 (4.4) |
Asthma | 841 (10.4) |
Emphysema | 72 (0.9) |
Cancer | 130 (1.6) |
Immunosuppressive therapy |
79 (1.0) |
Exposure, n = 8,084 | |
Contact with COVID-19 case |
360 (4.5) |
Prior testing | |
Tested for COVID-19 at any time | 716 (8.8) |
*Participants completed survey and had serum collected to test for SARS-CoV-2 IgG. n values indicate number of responses available in that category COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Page created: August 05, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.